These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 12643015)

  • 1. The EORTC and drug development. European Organisation for Research and Treatment of Cancer.
    Lacombe D; Fumoleau P; Zwierzina H; Twelves C; Hakansson L; Jayson G; Lehmann F; Verweij J; ;
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S19-23. PubMed ID: 11858959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The EORTC Laboratory Research Division. European Organisation for Research and Treatment of Cancer.
    Brünner N; Double J; Fichtner I; Gescher A; Newell D; Oosterhuis W; Price P
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S14-8. PubMed ID: 11858958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing targeted therapies for lung cancer.
    Gandara DR
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):648-9, 690. PubMed ID: 16258461
    [No Abstract]   [Full Text] [Related]  

  • 4. Addressing the challenge of intergroup studies in oncology: the EORTC experience. European Organisation for Research and Treatment of Cancer.
    Zurlo A; Therasse P
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S169-72. PubMed ID: 11858988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scientific review of EORTC trials: the functioning of the New Treatment Committee and Protocol Review Committee.
    Lardot C; Steward W; Van Glabbeke M; Armand JP
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S24-30. PubMed ID: 11858960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer drug development in Europe: a selection of new agents under development at the European Drug Development Network.
    Lacombe D; Butler-Smith A; Therasse P; Fumoleau P; Burtles S; Calvert H; Marsoni S; Sessa C; Verweij J
    Cancer Invest; 2003; 21(1):137-47. PubMed ID: 12643015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
    Perry WL; Weitzman A
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
    Pourquier P; Pommier Y
    Bull Cancer; 1998 Dec; Spec No():5-10. PubMed ID: 9932078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of novel anticancer drug targets.
    Buolamwini JK; Assefa H
    Methods Mol Med; 2003; 85():3-28. PubMed ID: 12710193
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel therapeutic approaches to advanced prostate cancer.
    Armstrong AJ; Carducci MA
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):271-82. PubMed ID: 16167000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenic inhibitors: a new therapeutic strategy in oncology.
    Gasparini G; Longo R; Toi M; Ferrara N
    Nat Clin Pract Oncol; 2005 Nov; 2(11):562-77. PubMed ID: 16270097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.